RedHill Biopharma (NASDAQ:RDHL) Price Target & New Coverage by Nomura
Nomura revealed to investors and clients in a recent research note that it began coverage on Redhill Biopharma (NASDAQ:RDHL) stock, with Buy rating and a $18.0 target.
The new coverage is well-received by equity traders, as NASDAQ:RDHL is right now trading 0.20% higher at $9.92 as of 12:03 PM New York time. RedHill Biopharma shares have [From2] 0% over the past 200 days, while the S&P 500 has increased 6.00% in the same time.
RedHill Biopharma (NASDAQ:RDHL) Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
RedHill Biopharma (NASDAQ:RDHL) traded up 0.20% on 26 January, hitting $9.92. A total of 45,889 shares of the company’s stock traded hands. This is down from average of 113,208 shares. RedHill Biopharma has a 52 week low of $8.16 and a 52 week high of $14.74. The company has a market cap of $170.10M and a P/E ratio of 0.
Get the latest RedHill Biopharma (NASDAQ:RDHL) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Nomura Has Initiated Coverage on RedHill Biopharma (NASDAQ:RDHL) Stock with Buy Rating and $18.0 Target appeared first on Octafinance.